HS-10541
/ Jiangsu Hansoh Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 30, 2026
Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.
(clinicaltrials.gov)
- P1 | N=636 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Monotherapy • New P1 trial • Oncology • Solid Tumor
May 13, 2026
Hansoh Pharmaceutical Group Company Limited…is pleased to announce that, HS-10541 tablets…has obtained the Clinical Trial Approval issued by the…NMPA of China, which is intended to be investigated in clinical trials for ’treatment of patients with KRAS G12C-mutated advanced solid tumors’
(HKEXnews)
New trial • Solid Tumor
1 to 2
Of
2
Go to page
1